Toxicology Drug Screening Market Forecasts to 2030 – Global Analysis By Type (Cardiovascular Disease Drug Screening, Obesity Drug Screening, Diabetes Drug Screening and Other Types), Test Type (Acute Systemic Toxicity, Dermal Toxicity, Carcinogenicity, Oc

Toxicology Drug Screening Market Forecasts to 2030 – Global Analysis By Type (Cardiovascular Disease Drug Screening, Obesity Drug Screening, Diabetes Drug Screening and Other Types), Test Type (Acute Systemic Toxicity, Dermal Toxicity, Carcinogenicity, Ocular Toxicity, Genotoxicity, Neurotoxicity, Organ-Specific Toxicity and Other Test Types), Technology, End User and by Geography

According to Stratistics MRC, the Global Toxicology Drug Screening Market is accounted for $13.34 billion in 2023 and is expected to reach $27.30 billion by 2030 growing at a CAGR of 10.77% during the forecast period. One essential part of medical diagnostics is toxicology drug screening, which looks for drugs or their metabolites in biological samples like blood, urine, or hair. In a number of contexts, such as workplace testing, forensic investigations, and clinical evaluations, this procedure is essential. Moreover, toxicology drug screening can detect a variety of substances, including toxins, illicit drugs, and prescription medications, by using advanced analytical techniques like chromatography-mass spectrometry and immunoassays.

According to the IFPMA's 2021 report, the annual R&D spending by the biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Growing number of cases of substance abuse

One of the main factors propelling the toxicology drug screening market is the rising incidence of substance abuse, which includes both conventional drugs and newly developed synthetic substances. Additionally, particularly in light of the opioid crisis, there is a greater need than ever for efficient screening methods that identifies and treats drug abuse. In response to this driver, the market has developed novel testing methodologies that can detect a wide range of substances, including new designer drugs that present challenges to established screening techniques.

Restraint:

Difficulties in identifying novel substances

The quick rise of designer drugs and new psychoactive substances (NPS), which continuously complicate conventional toxicology screening techniques, is one major barrier. As the world of substance abuse changes, screening assays find it challenging to keep up with the dynamic nature of illicit drug formulations. Furthermore, enhancing screening capabilities through ongoing research and development is necessary to adjust to the detection of novel compounds.

Opportunity:

Development of cutting-edge screening technologies

The development of more sophisticated and all-encompassing screening technologies has a great deal of potential. Improved sensitivity, specificity, and the capacity to detect a wider variety of substances can result from ongoing research and innovation in analytical techniques like mass spectrometry and chromatography. Moreover, putting money into state-of-the-art technologies puts stakeholders in a position to more accurately and efficiently handle the changing demands of toxicology screening.

Threat:

Designer drugs quick evolution

The development of designer drugs and novel psychoactive substances (NPS) presents a serious threat to established toxicology screening techniques. These substances are evolving quickly, which makes it difficult for screening assays to identify and detect new compounds. Additionally, this could result in false negative results and reduce the effectiveness of drug testing.

Covid-19 Impact

The COVID-19 pandemic has had a profound effect on the market for toxicology drug screening, changing healthcare priorities and procedures. Drug testing programs and other regular healthcare services have been disrupted as a result of the focus on solving the public health emergency. Although there was still a need for toxicology screening, especially for critical workers and in emergency rooms, the pandemic created difficulties for sample collection, laboratory operations, and general logistics. Furthermore, decisions to invest in cutting-edge toxicology technologies were influenced by budgetary constraints and economic uncertainties during the pandemic.

The Cardiovascular Disease Drug Screening segment is expected to be the largest during the forecast period

The cardiovascular disease drug screening segment is projected to hold the largest share. The world's leading causes of morbidity and mortality are cardiovascular diseases, which include ailments like dyslipidemia and hypertension. Thus, one of the most important aspects of pharmaceutical research and development is drug screening for cardiovascular diseases. Moreover, the identification of drugs and treatments that target heart and vascular health risk factors, such as blood pressure, cholesterol, and clotting factors, is central to the cardiovascular drug screening market.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

Over the course of the forecast period, the diagnostic laboratories segment is expected to have the highest CAGR. Diagnostic laboratories offer a wide variety of tests for the diagnosis and monitoring of diseases, which makes them essential to the healthcare process. Additionally, the need for advanced testing services has increased due to the rising prevalence of chronic conditions and the development of diagnostic technologies. Due to their crucial role in precision and personalized medicine, as well as their partnerships with pharmaceutical companies and healthcare providers, diagnostic laboratories are well-positioned for continued growth in this market.

Region with largest share:

North America is expected to hold the largest share. Many factors contribute to this prominence, including substantial investments in research and development, a well-established network of diagnostic laboratories, a high prevalence of chronic diseases, and an advanced healthcare infrastructure. The United States, in particular, is a major factor driving market growth because of its strong healthcare system and ongoing advancements in diagnostic technology. Furthermore, North America continues to dominate the market for diagnostic laboratories, in part because of the region's emphasis on personalized healthcare and precision medicine.

Region with highest CAGR:

The diagnostic laboratories market is expected to grow at the highest CAGR in the Asia-Pacific (APAC) region, due to factors such as growing demand for advanced diagnostic services, rising healthcare awareness, and the prevalence of infectious and chronic diseases. Alongside significant advancements in diagnostic technologies, nations like China, India, and Japan are investing heavily in their healthcare infrastructure. Moreover, the region's strong growth in the diagnostic laboratory market is also attributed to the emphasis on preventive healthcare and the adoption of precision medicine practices in several APAC countries.

Key players in the market

Some of the key players in Toxicology Drug Screening market include Covance, Inc., Agilent Technologies Inc., Enzo Life Sciences Inc., Danaher, Alere, Inc., BioReliance, Inc., Eurofins Scientific, Bio-Rad Laboratories Inc., Promega Corporation, GE Healthcare, Thermo Fisher Scientific Inc and Charles River Laboratories International Inc.

Key Developments:

In November 2023, Danaher will acquire all of the outstanding shares of Abcam for $24 per share in cash, for a total enterprise value of approximately $5.7bn including assumed indebtedness and net of acquired cash.

In September 2023, Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.

In July 2023, Bio-Rad Laboratories, Inc. and QIAGEN N.V., today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Types Covered:
• Cardiovascular Disease Drug Screening
• Obesity Drug Screening
• Diabetes Drug Screening
• Other Types



Test Types Covered:
• Acute Systemic Toxicity
• Dermal Toxicity
• Carcinogenicity
• Ocular Toxicity
• Genotoxicity
• Neurotoxicity
• Organ-Specific Toxicity
• Other Test Types

Technologies Covered:
• High-Throughput Screening
• Genomics
• Transcriptomics
• Toxicogenomics
• Molecular Screening
• Other Technologies

End Users Covered:
• Hospitals and Trauma Centers
• Forensic Laboratories
• Diagnostic Laboratories
• Rehabilitation Centers
• Pharmaceutical & Biotechnology Companies
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments

- Strategic recommendations for the new entrants

- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030

- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

- Strategic recommendations in key business segments based on the market estimations

- Competitive landscaping mapping the key common trends

- Company profiling with detailed strategies, financials, and recent developments

- Supply chain trends mapping the latest technological advancements